

INTRODUCTION	XVI
OBJECTIVES AND GOALS OF STUDY	XVI
CONTRIBUTION OF THE STUDY AND FOR WHOM	XVI
STUDY SCOPE AND FORMAT	XVII
METHODOLOGY	XVII
INFORMATION SOURCES	XVIII
RELATED BCC WORK CREDENTIALS INCLUDING WORK DONE BY OTHER AUTHORS	XVIII
ANALYST CREDENTIALS	XIX
BCC ON-LINE SERVICES	XIX
INTERNET	XIX
SUMMARY	XX
<i>SUMMARY TABLE THE U.S. MARKET FOR REGENERATIVE MEDICINE PRODUCTS USED IN BONE AND JOINT APPLICATIONS, THROUGH 2007 (\$ MILLIONS)</i>	XX
<i>SUMMARY FIGURE THE U.S. MARKET FOR REGENERATIVE MEDICINE PRODUCTS USED IN BONE AND JOINT APPLICATIONS, 2001, 2002 AND 2007 (\$ MILLIONS)</i>	XXI
OVERVIEW	1
THE GROWING MARKET FOR REGENERATIVE MEDICINE	1
WHAT IS REGENERATIVE MEDICINE?	1
BIOLOGY-BASED MEDICINE	2
APPROACHES USED IN REGENERATIVE MEDICINE	2
HUMAN SUBSTANCES	2
CELLS AND TISSUES	3
Tissue Engineering	3
The Importance of Scaffolding in Tissue Engineering	3
Blood Vessel Scaffolding	4
Massachusetts General/MIT	4
Duke University	5
Advanced Tissue Sciences	5
EMBRYONIC STEM CELLS	5
Therapeutic Cloning	6
ADULT STEM CELLS—JUST AS GOOD AS EMBRYONIC STEM CELLS	6
Genzyme	6
University of Minnesota	7
Marketers of Adult Stem Cells	8
SETTING THE STAGE FOR REGENERATIVE MEDICINE TO TREAT BONE AND JOINT DISORDERS	8
NOVEL MATERIALS	9
GENE THERAPY	9

Gene Therapy Trials Targeting Bone and Joint Diseases and Disorders	10
Food and Drug Administration Halts Gene Therapy Trials.....	11
THE USE OF BIOREACTORS IN REGENERATIVE MEDICINE	11
THE IMPACT OF GENOMICS	12
OTHER AREAS OF PROGRESS IN REGENERATIVE MEDICINE	12
CARDIOVASCULAR TECHNOLOGIES	12
Angiogenesis	12
Use of Angiogenesis in the Treatment of Heart Disease	13
Cardiac Cell Therapy.....	14
The Myocardial Patch.....	14
NEUROLOGICAL TECHNOLOGIES.....	15
Neurotransplantation in Stroke Patients.....	15
Embryonic Cell Transplant Therapy for Patients with Spinal Cord Injury	15
Use of Bone Morphogenic Proteins in the Treatment of Traumatic Spinal Cord Injury	16
SKIN TECHNOLOGIES.....	16
Skin Technologies (Continued)	17
APPLICATIONS TO BONE AND JOINT DISEASES AND DISORDERS	18
MAJOR DISEASES AND CONDITIONS AFFECTING BONES.....	18
OSTEOPOROSIS	18
Currently Available Products to Treat Osteoporosis	19
Bisphosphonates	19
Fosamax.....	20
Hormones	20
Evista	20
Forteo	21
Miacalcin.....	21
The Market for Products to Treat Osteoporosis.....	22
<i>TABLE 1 THE WORLDWIDE MARKET FOR DRUGS TO TREAT OSTEOPOROSIS, THROUGH 2007 (\$ MILLIONS)</i>	22
PAGET'S DISEASE.....	22
Currently Available Drugs to Treat Paget's Disease	23
Actonel.....	23
Aredia	23
Skelid.....	23
The Market for Products to Treat Paget's Disease	24
<i>TABLE 2 THE WORLDWIDE MARKET FOR DRUGS TO TREAT PAGET'S DISEASE, THROUGH 2007 (\$ MILLIONS)</i>	24
INJURIES AND DEGENERATIVE CONDITIONS.....	24
Hip Fractures.....	24
<i>TABLE 3 HIP FRACTURE VOLUMES, WORLDWIDE, THROUGH 2007</i>	25
<i>TABLE 4 HIP FRACTURE VOLUMES, U.S., THROUGH 2007</i>	25

TRADITIONAL TREATMENTS FOR BONE AND JOINT DISORDERS	25
FIGURE 1 THE U.S. MUSCULOSKELETAL PRODUCTS MARKET, 2002	26
FIGURE 2 THE U.S. RECONSTRUCTIVE DEVICE MARKET, 2002	27
Market Leaders	27
Joint Replacement Surgery	27
TABLE 5 HIP REPLACEMENT PROCEDURE VOLUMES, U.S., THROUGH 2007	28
FIGURE 3 HIP REPLACEMENT PROCEDURE VOLUMES, U.S., 2001, 2002 AND 2007.....	28
TABLE 6 HIP REPLACEMENT PROCEDURE VOLUMES IN SIX STATES, 2001.....	29
TABLE 7 THE HIP REPLACEMENT MARKET, WORLDWIDE, THROUGH 2007 (\$ MILLIONS).....	29
TABLE 8 THE HIP REPLACEMENT MARKET, U.S., THROUGH 2007 (\$ MILLIONS).....	29
Knee Replacements	30
TABLE 9 KNEE REPLACEMENT PROCEDURE VOLUMES, WORLDWIDE, THROUGH 2007.....	30
TABLE 10 KNEE REPLACEMENT PROCEDURE VOLUMES, U.S., THROUGH 2007.....	31
FIGURE 4 KNEE REPLACEMENT PROCEDURE VOLUMES, U.S., 2001, 2002 AND 2007.....	31
TABLE 11 THE KNEE REPLACEMENT MARKET, WORLDWIDE, THROUGH 2007 (\$ MILLIONS).....	32
TABLE 12 THE KNEE REPLACEMENT MARKET, U.S., THROUGH 2007 (\$ MILLIONS).....	32
TABLE 13 THE MARKET FOR UNICONDYLAR KNEE REPLACEMENT, U.S., THROUGH 2007 (\$ MILLIONS).....	32
Spinal Fusion	33
Indications for Spinal Fusion	33
The Spinal Fusion Procedure	34
The Spinal Fusion Procedure (Continued).....	35
Spinal Fusion Procedure Volumes	36
TABLE 14 SPINAL FUSION PROCEDURE VOLUMES, WORLDWIDE, THROUGH 2007.....	36
TABLE 15 SPINAL FUSION PROCEDURE VOLUMES, U.S., THROUGH 2007	36
FIGURE 5 SPINAL FUSION PROCEDURE VOLUMES, U.S., THROUGH 2007.....	37
TABLE 16 LUMBAR SPINAL FUSION PROCEDURE VOLUMES, U.S., THROUGH 2007.....	37
TABLE 17 POSTERIOR LUMBAR SPINAL FUSION PROCEDURE VOLUMES, U.S., THROUGH 2007.....	38
TABLE 18 CERVICAL SPINAL FUSION PROCEDURE VOLUMES, U.S., THROUGH 2007.....	38
The Market for Spinal Fusion Products	38
FIGURE 6 THE U.S. SPINAL PRODUCTS MARKET, 2002.....	39
TABLE 19 THE MARKET FOR INTERBODY FUSION DEVICE IMPLANTATION PROCEDURES, WORLDWIDE, THROUGH 2007 (\$ MILLIONS).....	39
TABLE 20 INTERBODY FUSION DEVICE IMPLANTATION PROCEDURE VOLUMES, U.S., THROUGH 2007	40
TOTAL BONE REPLACEMENT	40
LIMB LENGTHENING	40
LIMB LENGTHENING (CONTINUED).....	41
DISEASES AFFECTING JOINTS	42
OSTEOARTHRITIS	42

Osteoarthritis (Continued).....	43
Glucosamine and Chondroitin for the Treatment of Osteoarthritis	44
RHEUMATOID ARTHRITIS.....	45
TABLE 21 PREVALENCE OF RHEUMATOID ARTHRITIS, U.S., THROUGH 2007.....	45
Currently Available Drugs to Treat Rheumatoid Arthritis.....	46
Nonsteroidal Anti-inflammatory Drugs.....	46
COX-2 Inhibitors.....	47
Disease-Modifying Antirheumatic Drugs	47
Biological Response Modifiers to Treat Rheumatoid Arthritis	48
Enbrel	48
Kineret (Anakinra)	49
Antibody-based Drugs to Treat Rheumatoid Arthritis	49
Humira	50
Remicade	51
Downside of Currently Marketed Antibody Drugs	52
Antibody Drugs in Development to Treat Rheumatoid Arthritis	52
TABLE 22 THERAPEUTIC ANTIBODY PRODUCTS IN PHASE II OR LATER DEVELOPMENT FOR THE TREATMENT OF RHEUMATOID ARTHRITIS	52
TABLE 22 (CONTINUED)	53
The Market for DMARDs	53
TABLE 23 THE MARKET FOR DISEASE-MODIFYING ANTI-ARTHRITIC DRUGS TO TREAT RHEUMATOID ARTHRITIS, WORLDWIDE, THROUGH 2007 (\$ MILLIONS).....	53
FIGURE 7 THE MARKET FOR DISEASE-MODIFYING ANTI-ARTHRITIC DRUGS TO TREAT RHEUMATOID ARTHRITIS, WORLDWIDE, 2001, 2002 AND 2007 (\$ MILLIONS).....	54
Immunosuppressants	54
Drugs in Development to Treat Rheumatoid Arthritis	54
TABLE 24 NUMBER OF 2003 TRIALS OF DRUGS TO TREAT RHEUMATOID ARTHRTIS BY MECHANISM OF ACTION.....	55
PRODUCTS AND TECHNOLOGIES.....	56
REGENERATIVE TECHNOLOGIES.....	56
GENE- AND PROTEIN-BASED APPROACHES.....	56
Antibodies	56
The Importance of Antibody Drugs.....	57
Advantages of Monoclonal Antibody Drugs.....	58
Growth Factors	59
CELLS AND TISSUES	60
Tissue Engineering.....	61
Artificial Skin.....	61

Cartilage.....	62
Other Products.....	62
The Creation of Entire Organs.....	62
EMBRYONIC STEM CELLS.....	63
NOVEL MATERIALS/BIOMATERIALS	64
REGENERATIVE PRODUCTS TO TREAT BONE DISEASES	65
OSTEOBIOLOGICS.....	65
Bone Grafts	66
TABLE 25 BONE GRAFT PROCEDURE VOLUMES BY APPLICATION, U.S., THROUGH 2007.....	67
TABLE 26 BONE GRAFT PROCEDURE VOLUMES BY TYPE OF GRAFT, U.S., THROUGH 2007.....	67
FIGURE 8 BONE GRAFT PROCEDURE VOLUMES BY TYPE OF GRAFT, U.S., 2001, 2002 AND 2007.....	68
TABLE 27 COMPARISON OF BONE GRAFT MATERIALS	69
TABLE 28 TYPES OF SUBSTITUTE BONE GRAFTS.....	70
Autografts.....	70
Bioseed Grafts	71
Allografts	71
Allografts (Continued)	72
Risks Associated with Allografts	73
Demineralized Bone Matrix Products.....	73
TABLE 29 SELECTED DBM PRODUCT AND PERCENTAGE OF DEMINERALIZED BONE MATRIX.....	74
Accell.....	74
AlloGro and AlloMatrix.....	74
Connect Cervical Allograft.....	75
Coreograft and CorLok.....	75
DBM Carrier Product.....	75
DBX.....	75
Duet Lumbar Allograft.....	76
DynaCan.....	76
DynaGraft II.....	76
Graftech.....	76
Grafton.....	77
Opteform.....	77
OrthoBlast II.....	77
Osteofil.....	78
Solo Cervical Allograft.....	78
VivescOs	78
Xenografts	78
The Market for Allografts.....	79
TABLE 30 THE U.S. MARKET FOR PRECISION-MACHINED ALLOGRAFTS, THROUGH 2007 (\$ MILLIONS).....	79
Cell-Based Bone Graft Substitutes	80
Factor-based Bone Graft Substitutes.....	80

Bone Morphogenic Proteins	81
InductOs.....	82
InFUSE Bone Graft	82
Ne-Osteo	83
OP-1 Implant.....	84
Ossigel.....	85
Skelite	85
Ceramic-based Bone Graft Substitutes.....	86
Types of Ceramics	87
Alpha-BSM	88
BioGran.....	88
BioOss	88
BoneSource	88
Calcigen S	88
Collagraft Strip Bone Graft Matrix.....	88
Conduit TCP Granules	89
IsoTis Products.....	89
Mimix Bone Substitute Material.....	90
Norian SRS.....	90
OsteoGraf.....	90
Osteoset.....	90
Osteostim Resorbable Bone Graft Substitute.....	91
PerioGlas.....	91
Pro Osteon Implant 500	91
Vitoss.....	91
Polymer-based Bone Graft Substitutes.....	92
Bioplant Hard Tissue Replacement	92
Bioplant Hard Tissue Replacement (Continued).....	93
Cortoss	94
Healos.....	94
Immix Extenders and Immix CB.....	95
Polyactive.....	95
Poly(lactic-co-glycolic acid) Foam Matrix.....	96
Poly(propylene) Fumarate.....	96
Rhakoss	97
The Market for Bone Graft Products	97
TABLE 31 THE WORLDWIDE MARKET FOR BONE REPLACEMENT PRODUCTS, THROUGH 2007 (\$ MILLIONS).....	98
TABLE 32 THE U.S. MARKET FOR BONE REPLACEMENT PRODUCTS, THROUGH 2007 (\$ MILLIONS).....	98
FIGURE 9 THE U.S. MARKET FOR BONE REPLACEMENT PRODUCTS, 2001, 2002 AND 2007 (\$ MILLIONS).....	99
Regenerative Medicine Products in Development for Bone Applications	99

	Biologic/Synthetic Grafts.....	99
	Chrysalin	100
BONE GROWTH STIMULATORS.....		101
Types of Bone Growth Stimulation.....		102
Semi-invasive Direct Current		102
Invasive Direct Current.....		102
Pulsing Electromagnetic Fields.....		103
Marketers of Noninvasive Bone Growth Stimulators.....		103
EBI, Inc./Biomet.....		103
Orthofix/Medtronic		104
OrthoLogic/Johnson & Johnson		105
OrthoLogic/Johnson & Johnson (Continued)		106
Smith & Nephew.....		107
The Market for Noninvasive Bone Growth Stimulators.....		107
<i>TABLE 33 THE WORLDWIDE MARKET FOR NONINVASIVE BONE GROWTH</i>		
<i>STIMULATORS, THROUGH 2007 (\$ MILLIONS).....</i>		<i>108</i>
<i>FIGURE 10 THE WORLDWIDE MARKET FOR NONINVASIVE BONE GROWTH</i>		
<i>STIMULATORS, THROUGH 2007 (\$ MILLIONS).....</i>		<i>109</i>
<i>TABLE 34 THE U.S. MARKET FOR NONINVASIVE BONE GROWTH STIMULATORS,</i>		
<i>THROUGH 2007 (\$ MILLIONS).....</i>		<i>109</i>
Market Share by Manufacturer		110
<i>FIGURE 11 SHARE BY COMPANY OF THE NONINVASIVE BONE GROWTH</i>		
<i>STIMULATOR MARKET, U.S., 2002.....</i>		<i>110</i>
REGENERATIVE PRODUCTS TO TREAT DISEASED AND		
DAMAGED JOINTS.....		111
AUTOLOGOUS PRODUCTS.....		111
BioSeed-C Autologous 3D Chondrocyte Graft.....		111
Carticel®		112
CellActive Cartilage		113
Collagen Meniscus Implant.....		113
Immix Chondroflex.....		114
The Market for Tissue-Engineered Cartilage Products.....		114
<i>TABLE 35 THE U.S. MARKET FOR TISSUE-ENGINEERED CARTILAGE</i>		
<i>PRODUCTS, THROUGH 2007 (\$ MILLIONS).....</i>		<i>114</i>
COMPANIES WITH REGENERATIVE PRODUCTS IN		
DEVELOPMENT		114
Curis.....		115
Genzyme Biosurgery		115
Genzyme/Johns Hopkins University.....		115
IsoTis NV		116
Isto Technologies		116
Millenium Biologix		117
TiGenix NV		117
TiGenix NV (Continued).....		118
INDUSTRY		119

SUPPLIERS OF REGENERATIVE BONE AND JOINT PRODUCTS.....	119
PREMARKET NOTIFICATION—510(K).....	119
WHAT IS PREMARKET NOTIFICATION?	119
WHAT IS SUBSTANTIAL EQUIVALENCE?	120
WHO IS REQUIRED TO SUBMIT A 510(K)?	120
WHEN A 510(K) IS REQUIRED	121
WHEN A 501(K) IS NOT REQUIRED	122
THE MODERNIZATION ACT AND THE 510(K) SUBMISSION PROCESS—DIFFERENT TYPES OF SUBMISSIONS FOR DIFFERING SITUATIONS.....	123
MEDICAL DEVICES REVIEWED BY THE CENTER FOR BIOLOGIC, EVALUATION, RESEARCH.....	124
THIRD PARTY REVIEW PROGRAM.....	124
REGULATORY ISSUES FOR CELLULAR AND TISSUE-BASED PRODUCTS	124
CHANGES IN THE REGULATION OF DEMINERALIZED BONE PRODUCTS.....	125
INDUSTRY GROWTH.....	125
Bankruptcies.....	125
Regulatory Issues.....	126
Development Issues	127
Pricing	127
Capital.....	127
ADVANCED TISSUE SCIENCES	128
ORGANOGENESIS	128
CURIS EXITS THE TISSUE ENGINEERING MARKET	129
THE TISSUE-ENGINEERING MARKET IN EUROPE.....	129
THE DEVELOPMENT OF REGENERATIVE MEDICINES IN JAPAN	129
THE DEVELOPMENT ... IN JAPAN (CONTINUED)	130
COMPANY PROFILES	131
BIOMET ORTHOPEDICS, INC.....	131
BUSINESS OVERVIEW.....	131
FINANCIAL INFORMATION.....	131
LEADING PRODUCTS.....	131
CORPORATE STRATEGY	132
BIOTISSUE TECHNOLOGIES AG	133
BUSINESS OVERVIEW.....	133
LEADING PRODUCTS.....	134
CORPORATE STRATEGY	134
CENTERPULSE, INC.	134
BUSINESS OVERVIEW.....	134
FINANCIAL INFORMATION.....	135
LEADING PRODUCTS.....	135
CORPORATE STRATEGY	135

CORTEK, INC.....	136
BUSINESS OVERVIEW.....	136
LEADING PRODUCTS.....	136
CORPORATE STRATEGY	137
CURIS, INC.....	138
BUSINESS OVERVIEW.....	138
FINANCIAL INFORMATION.....	138
LEADING PRODUCTS.....	138
CORPORATE STRATEGY	139
Development Terminations.....	139
Reorganization.....	139
Product Focus	139
Johnson & Johnson Agreements.....	140
Stryker Agreements	140
Other Agreements	141
Patents	141
GENSCI REGENERATION SCIENCES INC.....	142
BUSINESS OVERVIEW.....	142
FINANCIAL INFORMATION.....	142
LEADING PRODUCTS.....	142
CORPORATE STRATEGY	143
GENZYME BIOSURGERY	144
BUSINESS OVERVIEW.....	144
FINANCIAL INFORMATION.....	144
LEADING PRODUCTS.....	144
CORPORATE STRATEGY	145
INTEGRA LIFESCIENCES HOLDINGS CORP.....	146
BUSINESS OVERVIEW.....	146
FINANCIAL INFORMATION.....	146
LEADING PRODUCTS.....	146
CORPORATE STRATEGY	146
INTERPORE CROSS INTERNATIONAL.....	146
BUSINESS OVERVIEW.....	146
FINANCIAL INFORMATION.....	147
LEADING PRODUCTS.....	147
<i>TABLE 36 INTERPORE CROSS'S MARKETED ORTHOBIOLOGIC PRODUCTS.....</i>	<i>148</i>
<i>TABLE 37 INTERPORE CROSS'S NEAR-TERM PRODUCT PIPELINE</i>	<i>149</i>
CORPORATE STRATEGY	149
ISOTIS BV.....	149
BUSINESS OVERVIEW.....	149
LEADING PRODUCTS.....	149
CORPORATE STRATEGY	150
ISTO TECHNOLOGIES, INC.	150
BUSINESS OVERVIEW.....	150
LEADING PRODUCTS.....	150

CORPORATE STRATEGY	151
MEDTRONIC, INC.	151
BUSINESS OVERVIEW	151
FINANCIAL INFORMATION	151
LEADING PRODUCTS.....	152
CORPORATE STRATEGY	152
MILLENIUUM BIOLOGIX INC.	152
BUSINESS OVERVIEW	152
LEADING PRODUCTS.....	153
CORPORATE STRATEGY	154
NEUCOLL INC.	155
BUSINESS OVERVIEW	155
LEADING PRODUCTS.....	155
CORPORATE STRATEGY	156
ORQUEST, INC.	156
BUSINESS OVERVIEW	156
LEADING PRODUCTS.....	156
<i>TABLE 38 ORQUEST'S PRODUCT PIPELINE</i>	<i>157</i>
CORPORATE STRATEGY	158
ORTHOFIX INTERNATIONAL N.V.	159
BUSINESS OVERVIEW	159
FINANCIAL INFORMATION.....	159
LEADING PRODUCTS.....	159
Leading Products (Continued)	160
CORPORATE STRATEGY	161
ORTHOLOGIC CORP.....	162
BUSINESS OVERVIEW.....	162
FINANCIAL INFORMATION.....	163
LEADING PRODUCTS.....	163
OL1000.....	163
SpinaLogic.....	164
Chrysalin.....	165
CORPORATE STRATEGY	166
ORTHOVITA, INC.	166
BUSINESS OVERVIEW.....	166
FINANCIAL INFORMATION.....	167
LEADING PRODUCTS.....	167
Leading Products (Continued)	168
<i>TABLE 39 ORTHOVITA'S PRODUCT PIPELINE</i>	<i>169</i>
CORPORATE STRATEGY	169
OSTEOBIOLOGICS, INC.....	169
BUSINESS OVERVIEW	169
LEADING PRODUCTS.....	170
CORPORATE STRATEGY	170
<i>TABLE 40 OSTEOBIOLOGICS' PATENT PORTFOLIO</i>	<i>171</i>

OSTEOTECH INC.	171
BUSINESS OVERVIEW	171
FINANCIAL INFORMATION	172
LEADING PRODUCTS.....	172
CORPORATE STRATEGY	173
Corporate Strategy (Continued).....	174
Corporate Strategy (Continued).....	175
REGEN BIOLOGICS, INC.	176
BUSINESS OVERVIEW	176
LEADING PRODUCTS.....	176
CORPORATE STRATEGY	177
STRYKER CORP.	177
BUSINESS OVERVIEW	177
FINANCIAL INFORMATION	178
LEADING PRODUCTS.....	178
CORPORATE STRATEGY	179
TIGENIX N.V.	180
BUSINESS OVERVIEW	180
LEADING PRODUCTS.....	180
CORPORATE STRATEGY	181
WRIGHT MEDICAL GROUP, INC.....	182
FINANCIAL INFORMATION	182
LEADING PRODUCTS.....	182
CORPORATE STRATEGY	183